Technology
Health
Pharmaceutical

Gemphire Therapeutics

$0.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.012 (-1.66%) Today
$0.00 (0.00%) As of 3:56 PM EDT after-hours

Why Robinhood?

You can buy or sell GEMP and other stocks, options, ETFs, and crypto commission-free!

About GEMP

Gemphire Therapeutics Inc. Common Stock, also called Gemphire Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. Read More It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.

Employees
9
Headquarters
Livonia, Michigan
Founded
2014
Market Cap
10.56M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
41.45K
High Today
$0.74
Low Today
$0.7005
Open Price
$0.74
Volume
29.68K
52 Week High
$7.93
52 Week Low
$0.5698

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2016 IPO
US

GEMP News

BenzingaJun 26

Gemphire Therapeutics Falls 20% After Oral Cholesterol Drug Trial Results

440

GEMP Earnings

-$0.66
-$0.53
-$0.39
-$0.26
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 9, After Hours

More GEMP News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.